Study to determine whether Remifentanil is effective for treating procedural pain in neonates

This study is testing whether a pain relief medication called remifentanil, given as a continuous drip, can reduce pain in premature and newborn babies who need a central venous line (a small tube placed into a large vein) inserted as part of their medical care. Pain from this procedure in newborns is a serious concern. Researchers will compare pain scores in babies who receive remifentanil versus those who do not. You may be eligible if: - Your baby is medically stable - Your baby is currently an inpatient in the NICU at John Hunter Children's Hospital - Your baby needs a central venous catheter placed for their medical care - Your baby is between 24 and 44 weeks corrected gestational age at the time of the procedure You may NOT be eligible if: - Your baby has previously taken part in this study - Your baby has major congenital anomalies - Your baby has severe hypoxic ischaemic encephalopathy (brain injury from lack of oxygen) - Your baby is having active clinical seizures - Your baby is currently on a muscle relaxant medication - The central line insertion is an emergency procedure - Your baby does not have peripheral venous access for the study drug Talk to your doctor about whether this trial might be right for you.